Voyager Therapeutics Inc

VT6

Company Profile

  • Business description

    Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

  • Contact

    75 Hayden Avenue
    LexingtonMA02421
    USA

    T: +1 857 259-5340

    E: [email protected]

    https://www.voyagertherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    141

Stocks News & Analysis

stocks

Undervalued tech share oversold on AI fears

Has the market overlooked this ASX tech share?
stocks

Margins have bottomed for ASX listed consumer goods company

Impact of tariffs have been priced in.
stocks

SpaceX rally continues, expanding sky-high valuations

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,031.209.400.10%
CAC 408,367.1953.95-0.64%
DAX 4024,925.4260.40-0.24%
Dow JONES (US)51,564.7072.150.14%
FTSE 10010,359.084.19-0.04%
HKSE23,768.52156.29-0.65%
NASDAQ26,517.93496.281.91%
Nikkei 22572,353.961,103.901.55%
NZX 50 Index13,446.0549.58-0.37%
S&P 5007,500.5880.481.08%
S&P/ASX 2008,816.1014.200.16%
SSE Composite Index4,163.1072.621.78%

Market Movers